AMOXICILLIN; CLAVULANATE POTASSIUM | A090227 | SANDOZ INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Aurobindo Pharma USA, Inc FDA-2019-P-5237 · 5 docket documents Aurobindo Pharma USA, Inc. filed this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA designate Sandoz Inc.'s approved generic Amoxicillin and Clavulanate Potassium Extended Release Tablets 1000 mg/62.5 mg (ANDA #090227) as an alternative ref | 505(q) | 2019-11-06 | Open | Aurobindo Pharma USA, Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$5.92
per ea
Lowest NADAC/Unit
$5.92
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00781194339AMOX-CLAV ER 1,000-62.5 MG TAB | $5.92 | EA | Generic | — | 2026-06-17 |
| 00781194382AMOX-CLAV ER 1,000-62.5 MG TAB | $5.92 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.